FK-GI101
Alternative Names: FK-GI-101Latest Information Update: 08 Oct 2025
At a glance
- Originator CellVax Therapeutics
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Biliary cancer; Colorectal cancer; Gastric cancer; Pancreatic cancer
Most Recent Events
- 05 Aug 2025 CellVax Therapeutics has patent protection for covering the composition, matter, method of use, and preparation (CellVax Therapeutics pipeline, August 2025)
- 29 Jul 2025 Phase-I clinical trials in Biliary cancer (Intradermal)
- 29 Jul 2025 Phase-I clinical trials in Colorectal cancer (Intradermal)